BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

17 articles for JG Varnes

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.EBI
Astrazeneca
Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.EBI
Astrazeneca
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.EBI
Bristol-Myers Squibb Research and Development
Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).EBI
Astrazeneca Pharmaceuticals
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.EBI
Pharmaceutical Research Institute
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-EBI
Astrazeneca
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.EBI
Astrazeneca
Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833.EBI
Astrazeneca
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.EBI
Bristol-Myers Squibb
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.EBI
Astrazeneca
Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors.EBI
Astrazeneca
Bicyclo((aryl)methyl)benzamides as inhibitors of GlyT1.EBI
Astrazeneca
Substituted N-phenethyltriazoloneacetamides and use thereofBDB
Bayer Intellectual Property
Heterocyclic compounds containing an indole coreBDB
Boehringer Ingelheim International